Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 82, Issue 1, 2008, Pages 34-40

  Caton, Alissa R ^a,b   Bell, Erin M ^a   Druschel, Charlotte M ^a,b   Werler, Martha M ^c   Mitchell, Allen A ^c   Browne, Marilyn L ^a,b   McNutt, Louise Anne ^a   Romitti, Paul A ^d   Olney, Richard S ^e   Correa, Adolfo ^e  

^a UNIVERSITY AT ALBANY   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Antihypertensive medications; Hypospadias; Maternal hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LABETALOL; METHYLDOPA; VASODILATOR AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPOSPADIAS; INFANT; MAJOR CLINICAL STUDY; MALE; MATERNAL HYPERTENSION; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SELF REPORT;

ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; HYPOSPADIAS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 38549160110     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20415     Document Type: Article

References (31)

1. Afifi Y, Churchill D. 2003. Pharmacological treatment of hypertension in pregnancy. Curr Pharm Des 9:1745-1753.
2. Akre O, Lipworth L, Cnattingius S, et al. 1999. Risk factor patterns for cryptorchidism and hypospadias. Epidemiology 10:364-369.
3. Aschim EL, Haugen TB, Tretli S, et al. 2004. Risk factors for hypospadias in Norwegian boys - association with testicular dysgenesis syndrome. Int J Androl 27:213-221.
4. Briggs GG, Freeman RK, Yaffe SJ, eds. 1998. Drugs in Pregnancy and Lactation. Baltimore: Williams & Wilkins.
5. Briggs GG, Freeman RK, Yaffe SJ, eds. 2003. Beta blockers. Drugs in Pregnancy and Lactation Update 16:10-15.
6. Czeizel A. 1989. Teratogenicity of ergotamine. J Med Genet 26:69-70.
7. Han JY, Nava-Ocampo AA, Koren G. 2005. Unintended pregnancies and exposure to potential human teratogens. Birth Defects Res A Clin Mol Teratol 73:245-248.
8. Heinonen OP, Slone D, Shapiro S. 1977. Birth Defects and Drugs in Pregnancy. Littleton: PSG Publishing Co.
9. Hussain N, Chaghtai A, Herndon CD, et al. 2002. Hypospadias and early gestation growth restriction in infants. Pediatrics 109:473-478.
10. Kallen BA. 2005. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto) 45:44-51.
11. Kliman HJ. 2000. Uteroplacental blood flow. The story of decidualization, menstruation, and trophoblast invasion. Am J Pathol 157:1759-1768.
12. Lydakis C, Lip GY, Beevers M, et al. 1999. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 12:541-547.
13. Magee LA. 2001. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf 24:457-474.
14. Manson JM, Carr MC. 2003. Molecular epidemiology of hypospadias: review of genetic and environmental risk factors. Birth Defects Res A Clin Mol Teratol 67:825-836.
15. Mayhew TM, Charnock-Jones DS, Kaufmann P. 2004. Aspects of human fetoplacental vasculogenesis and angiogenesis. III. Changes in complicated pregnancies. Placenta 25:127-139.
16. Mitchell AA. 2000. Special considerations in studies of drug-induced birth defects. In: Strom BL, editor. Pharmacoepidemiology. New York: John Wiley & Sons, Ltd. p 749-763.
17. Mitchell AA, Cottler LB, Shapiro S. 1986. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 123:670-676.
18. Moller H, Weidner IS. 1999. Epidemiology of cryptorchidism and hypospadias. Epidemiology 10:352-354.
19. Mulrow CD, Chiquette E, Ferrer RL, et al. 2000. Management of chronic hypertension during pregnancy. Evid Rep Technol Assess (Summ)1-4.
20. National High Blood Pressure Education Program (NHBPEP). 2000. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 183:S1-S22.
21. National High Blood Pressure Education Program (NHBPEP). 2004. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 04-5230.
22. Quan A. 2006. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 82:23-28.
23. Rasmussen SA, Olney RS, Holmes LB, et al. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67:193-201.
24. Rockenbauer M, Olsen J, Czeizel AE, et al. 2001. Recall bias in a case-control surveillance system on the use of medicine during pregnancy. Epidemiology 12:461-466.
25. Sibai BM. 2002. Chronic hypertension in pregnancy. Obstet Gynecol 100:369-377.
26. Sorensen HT, Czeizel AE, Rockenbauer M, et al. 2001. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand 80:397-401.
27. Sorensen HT, Pedersen L, Norgaard M, et al. 2005. Maternal asthma, preeclampsia and risk of hypospadias. Epidemiology 16:806-807.
28. von Dadelszen P, Magee LA. 2002. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 24:941-945.
29. Ward RM. 2001. Difficulties in the study of adverse fetal and neonatal effects of drug therapy during pregnancy. Semin Perinatol 25:191-195.
30. Werler MM, Pober BR, Nelson K, et al. 1989. Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol 129:415-421.
31. Yoon PW, Rasmussen SA, Lynberg MC, et al. 2001. The National Birth Defects Prevention Study. Public Health Rep 116 Suppl 1:32-40.